Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Avoid Anticoagulation After Intracerebral Haemorrhage
2024-514094-22-00Phase 3Authorised
- Sponsor
- CHU de Lille
- Start
- Oct 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of apixaban in nonvalvular atrial fibrillation (NVAF) and intracerebral hemorrhage (ICH) (3 arms), sponsored by CHU de Lille. Primary endpoint: Composite of fatal or life-threatening and major vascular events. Planned start Oct 2024; status: authorised.
02
Drugs
apixaban
03
Conditions
nonvalvular atrial fibrillation (NVAF)intracerebral hemorrhage (ICH)
Beyond the preview
Go deeper on 2024-514094-22-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-514094-22-00.